Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...
Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...
The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...
MedPage Today on MSN13h
Policy Fallout Continues; Rise in Lung Cancer Screening; Going Public With DenialsAn artificial intelligence-aided program accurately predicted 5-year survival for early breast cancer on the basis of a tumor's location. (JCO Clinical Cancer Informatics) Actor D ...
In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...
Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback